I critique Baxter International's capital allocation decisions, stating the stock is not suitable for popular investment strategies. See why I rate BAX a sell.
Novartis expects profit and sales to grow further this year after beating analysts' expectations in the fourth quarter, boosted by revenue from its key drugs.
The funds will be strategically used to diversify Sammmm's product portfolio, amplify brand visibility, and establish a strong multi-channel footprint.
DUBLIN, Ohio, Jan. 30, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) ("reAlpha" or the "Company"), a real estate technology company developing and commercializing artificial intelligence ...